Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00090051
Status:
COMPLETED
Last Update Posted:
2017-08-01
First Post:
2004-08-23
Brief Title:
FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia CLL in Relapsed Patients
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
Open-label Multicenter Randomized Comparative Phase III Study to Evaluate the Efficacy and Safety of FCR vs FC Alone in Previously Treated Patients With CD20 Positive B-cell CLL
Status:
COMPLETED
Status Verified Date:
2017-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to provide treatment for patients who have chronic lymphocytic leukemia CLL and to compare the use of rituximab added to fludarabinecyclophosphamide FC with FC alone to determine if rituximab lengthens the time a patient remains free of leukemia symptoms
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| BO17072 | None | None | None |